Overall, our data shows that emodin can significantly downregulate the expression of CXCR4, a key receptor involved in the crosstalk between tumor cells and its microenvironment, which contributes to its observed in vivo anti-metastatic effects. This evidence concerns the gene CXCR4 and neoplasm.